Related Experiment Videos
Overcoming methotrexate resistance by a lipophilic antifolate (BW 301U): from theory to models to practice
Abstract:
We have provided a rationale for the clinical use of a new lipid-soluble folate antagonist, BW 301U, in terms of its potential for killing several classes of methotrexate-resistant cells. As part of a Phase I evaluation of this agent we studied normal bone marrow from cancer patients and their metabolic susceptibility to either BW 301U or to MTX and then repeated the observations at the end of five days of BW 301U infusions. Both inhibitors were roughly comparable at equimolar concentrations prior to therapy, but a relative resistance developed to MTX after BW 301U treatment. Such findings were replicated in an in vitro HL-60 cell culture system that was exposed to BW 301U. Some possible mechanisms for this unusual collateral resistance are discussed.
Insights
A new drug, BW 301U, shows promise against methotrexate-resistant cells. Studies indicate BW 301U may cause collateral resistance to methotrexate, a finding replicated in cell cultures.
Area of Science:
- Pharmacology
- Oncology
- Cell Biology
Background:
- Methotrexate (MTX) is a cornerstone chemotherapy agent.
- Drug resistance, particularly to MTX, is a significant clinical challenge in cancer treatment.
- Lipid-soluble folate antagonists represent a potential strategy to overcome resistance.
Purpose of the Study:
- To evaluate the clinical rationale for using BW 301U, a novel lipid-soluble folate antagonist.
- To assess the metabolic susceptibility of normal bone marrow to BW 301U and MTX.
- To investigate the development of resistance to MTX following BW 301U treatment.
Main Methods:
- Phase I clinical evaluation of BW 301U in cancer patients.
- Metabolic susceptibility studies of bone marrow to BW 301U and MTX.
- In vitro experiments using HL-60 cell cultures exposed to BW 301U.
Main Results:
- BW 301U and MTX showed comparable efficacy at equimolar concentrations initially.
- A relative resistance to MTX developed in bone marrow after BW 301U infusions.
- This collateral resistance phenomenon was successfully replicated in HL-60 cell cultures.
Conclusions:
- BW 301U demonstrates potential in targeting methotrexate-resistant cancer cells.
- The development of collateral resistance to MTX following BW 301U treatment is a notable finding.
- Further investigation into the mechanisms of this unusual collateral resistance is warranted.